JP2012188427A - 徐放性アミノピリジン組成物の使用方法 - Google Patents
徐放性アミノピリジン組成物の使用方法 Download PDFInfo
- Publication number
- JP2012188427A JP2012188427A JP2012100498A JP2012100498A JP2012188427A JP 2012188427 A JP2012188427 A JP 2012188427A JP 2012100498 A JP2012100498 A JP 2012100498A JP 2012100498 A JP2012100498 A JP 2012100498A JP 2012188427 A JP2012188427 A JP 2012188427A
- Authority
- JP
- Japan
- Prior art keywords
- aminopyridine
- treatment
- treatment period
- effective amount
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【解決手段】組成物放出マトリックス中に分散された治療的有効量のアミノピリジンを有する薬学的組成物であって、例えば、錠剤などの安定な徐放性傾向投薬処方に処方され、患者への投与によって約12時間の期間、治療上有効な血漿レベルのアミノピリジンを提供するものである薬学的組成物、及び多発性硬化症を含む様々な神経疾患を治療するための前記組成物の使用。例えば、徐放性ファムプリジン組成物での治療に反応した個人を同定する工程を含む、治療に対する反応性に基づいて個人を選択する方法。
【選択図】図10
Description
本出願は、2004年4月9日に出願された米国仮出願番号第60/560,894号に対して優先権を主張するものである。
Claims (20)
- 歩行速度を増進するための方法であって、
1日2回徐放性アミノピリジン組成物の有効量を、多発性硬化症を患った患者へ投与する工程を有し、
前記有効量は、約15ミリグラム未満のアミノピリジンである、方法。 - 請求項1の方法において、
前記有効量は、約10〜約15ミリグラムのアミノピリジンである。 - 請求項1の方法において、
前記有効量は、約10ミリグラムのアミノピリジンである。 - 請求項1の方法において、
前記アミノピリジンは、4−アミノピリジンである。 - 請求項4の方法において、
前記徐放性4−アミノピリジン組成物は、約1.0〜3.5のCmax:Cτ比を示すものである。 - 請求項1の方法において、
前記1日2回の投与は、約12時間毎になされるものである。 - 下肢筋緊張を改善する方法であって、
1日2回徐放性アミノピリジン組成物の有効量を、多発性硬化症を患った患者へ投与する工程を有し、
前記有効量は、約15ミリグラム以下のアミノピリジンである、方法。 - 請求項7の方法において、
前記有効量は、約10〜約15ミリグラムのアミノピリジンである。 - 請求項7の方法において、
前記有効量は、約10ミリグラムのアミノピリジンである。 - 請求項7の方法において、
前記アミノピリジンは、4−アミノピリジンである。 - 請求項10の方法において、
前記徐放性4−アミノピリジン組成物は、約1.0〜3.5のCmax:Cτ比を示すものである。 - 下肢筋強度を改善する方法であって、
1日2回徐放性アミノピリジン組成物の有効量を、多発性硬化症を患った患者へ投与する工程を有し、
前記有効量は、約15ミリグラム以下のアミノピリジンである、方法。 - 請求項12の方法において、
前記有効量は、約10〜約15ミリグラムのアミノピリジンである。 - 請求項12の方法において、
前記有効量は、約10ミリグラムのアミノピリジンである。 - 請求項12の方法において、
前記アミノピリジンは、4−アミノピリジンである。 - 請求項15の方法において、
前記徐放性4−アミノピリジン組成物は、約1.0〜3.5のCmax:Cτ比を示すものである。 - 治療に対する反応性に基づいて個人を選択する方法であって、
多数の個人を同定する工程と、
治療期間前に各個人にテストを実施する工程と、
治療期間に1若しくはそれ以上の前記個人に治療を実施する工程と、
治療期間に各個人に複数回テストを実施する工程と、
1若しくはそれ以上の個人を選択する工程とを有し、
前記選択された個人は、前記治療期間前に実施されたテストと比較して、前記治療期間に実施されたテストの大部分の間において、改善された能力を示すものである、方法。 - 請求項17の方法であって、この方法はさらに、
治療期間後に各個人にテストを実施する工程を有し、
前記選択された個人はさらに、前記治療期間後に実施されたテストと比較して、前記治療期間に実施されたテストの大部分の間において、改善された能力を示すものである。 - 請求項17の方法において、
前記治療は、治療薬を有するものである。 - 治療に対する反応性に基づいて個人を選択する工程であって、
多数の個人を同定する工程と、
治療期間前に各個人にテストを実施する工程と、
治療期間に1若しくはそれ以上の前記個人に治療を実施する工程と、
治療期間に各個人に複数回テストを実施する工程と、
治療期間後に各個人へテストを実施する工程と、
1若しくはそれ以上の個人を選択する工程とを有し、
前記選択された個人は、前記治療期間前に実施されたテスト及び治前記療期間後に実施されたテストのより良い能力と比較して、治療期間に実施されたテストの大部分の間、改善された能力を示すものである、方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56089404P | 2004-04-09 | 2004-04-09 | |
US60/560,894 | 2004-04-09 | ||
US11/102,559 US8354437B2 (en) | 2004-04-09 | 2005-04-08 | Method of using sustained release aminopyridine compositions |
US11/102,559 | 2005-04-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507570A Division JP5736100B2 (ja) | 2004-04-09 | 2005-04-11 | 徐放性アミノピリジン組成物の使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012188427A true JP2012188427A (ja) | 2012-10-04 |
Family
ID=35061389
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507570A Active JP5736100B2 (ja) | 2004-04-09 | 2005-04-11 | 徐放性アミノピリジン組成物の使用方法 |
JP2012100498A Pending JP2012188427A (ja) | 2004-04-09 | 2012-04-25 | 徐放性アミノピリジン組成物の使用方法 |
JP2014259950A Active JP5914626B2 (ja) | 2004-04-09 | 2014-12-24 | 徐放性アミノピリジン組成物の使用方法 |
JP2015114746A Withdrawn JP2015157861A (ja) | 2004-04-09 | 2015-06-05 | 徐放性アミノピリジン組成物の使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507570A Active JP5736100B2 (ja) | 2004-04-09 | 2005-04-11 | 徐放性アミノピリジン組成物の使用方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014259950A Active JP5914626B2 (ja) | 2004-04-09 | 2014-12-24 | 徐放性アミノピリジン組成物の使用方法 |
JP2015114746A Withdrawn JP2015157861A (ja) | 2004-04-09 | 2015-06-05 | 徐放性アミノピリジン組成物の使用方法 |
Country Status (21)
Country | Link |
---|---|
US (13) | US8354437B2 (ja) |
EP (5) | EP2422782A1 (ja) |
JP (4) | JP5736100B2 (ja) |
AT (1) | ATE511841T1 (ja) |
AU (1) | AU2005232732B2 (ja) |
CA (2) | CA2562277C (ja) |
CY (4) | CY1111754T1 (ja) |
DK (2) | DK1732548T4 (ja) |
ES (2) | ES2367707T5 (ja) |
FI (2) | FI1732548T4 (ja) |
HK (1) | HK1162971A1 (ja) |
HR (2) | HRP20110497T4 (ja) |
HU (1) | HUE046320T2 (ja) |
LU (2) | LU91933I2 (ja) |
ME (2) | ME01721B (ja) |
MX (3) | MXPA06011648A (ja) |
PL (2) | PL2377536T5 (ja) |
PT (2) | PT2377536E (ja) |
RS (2) | RS51808B2 (ja) |
SI (2) | SI2377536T2 (ja) |
WO (1) | WO2005099701A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
AU2013206188B2 (en) * | 2005-09-23 | 2016-04-14 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
UY32109A (es) * | 2008-09-10 | 2010-04-30 | Acorda Therapeutics Inc | Métodos para utilizar composiciones de liberación sostenida de aminopiridina |
KR20170034452A (ko) * | 2009-02-11 | 2017-03-28 | 아코르다 쎄라퓨틱스 인코포레이티드 | 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법 |
JO3348B1 (ar) * | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
AR078323A1 (es) * | 2009-09-04 | 2011-11-02 | Acorda Therapeutics Inc | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple |
US20130030025A1 (en) | 2011-01-28 | 2013-01-31 | Wessel Thomas C | Use of potassium channel blockers to treat cerebral palsy |
US8924325B1 (en) * | 2011-02-08 | 2014-12-30 | Lockheed Martin Corporation | Computerized target hostility determination and countermeasure |
CA2840591A1 (en) | 2011-06-30 | 2013-01-03 | Biomarin Pharmaceuticals, Inc. | Methods of administering 3,4-diaminopyridine |
TWI592156B (zh) | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
BR112014020102A8 (pt) | 2012-02-13 | 2017-07-11 | Acorda Therapeutics Inc | Método para o tratamento de uma insuficiência de marcha e/ou equilíbrio em um paciente com esclerose múltipla, método para o tramento de uma deficiência no equilíbrio estacionário e método para aumentar o comprimento do passo, diminuir a largura do passo ou diminuir a oscilação |
WO2014028387A1 (en) | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
WO2014093475A1 (en) | 2012-12-11 | 2014-06-19 | Acorda Therapeutics, Inc. | Methods for treating parkinson's disease using aminopyridines |
PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
US9993429B2 (en) * | 2013-03-15 | 2018-06-12 | University Of Rochester | Composition and methods for the treatment of peripheral nerve injury |
EP3243516A1 (en) | 2013-04-15 | 2017-11-15 | Acorda Therapeutics, Inc. | Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines |
HRP20211269T1 (hr) | 2015-02-08 | 2022-01-21 | Alkermes Pharma Ireland Limited | Kompozicije prolijeka na bazi monometil fumarata |
RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
US10172842B2 (en) | 2015-09-11 | 2019-01-08 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
WO2017058869A1 (en) | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
EP3606510A1 (en) | 2017-04-06 | 2020-02-12 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1082804A (en) | 1912-11-19 | 1913-12-30 | Gerald G Griffin | Confetti-machine. |
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
CH415963A (de) | 1964-09-04 | 1966-06-30 | Wander Ag Dr A | Masse zur Herstellung von Tabletten mit protrahierter Wirkung |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4508715A (en) | 1981-07-01 | 1985-04-02 | University Of Georgia Research Foundation, Inc. | Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs |
US4386095A (en) | 1982-02-22 | 1983-05-31 | Cornell Research Foundation, Inc. | Diaminopyridines to improve cognition |
IE53703B1 (en) | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
IE54286B1 (en) | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
US4851230A (en) | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
IE56459B1 (en) | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4562196A (en) | 1984-04-06 | 1985-12-31 | Nelson Research & Development | 2,4-Diaminopyridine as a pharmacologic agent |
JPS6124516A (ja) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
US4812447A (en) | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
US4760092A (en) | 1985-10-29 | 1988-07-26 | The Rockefeller University | Treatment of demyelinating diseases |
US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
FI895821A0 (fi) | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
TW200462B (ja) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
DE4321030A1 (de) * | 1993-06-24 | 1995-01-05 | Bayer Ag | 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5952357A (en) | 1993-12-23 | 1999-09-14 | Cornell Research Foundation, Inc. | Treating diseases of the anterior horn cells |
US6284473B1 (en) | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
US6288026B1 (en) | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
US6600399B1 (en) | 2002-02-05 | 2003-07-29 | Roland Pierre Trandafir | Transducer motor/generator assembly |
WO2004082684A1 (en) | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
EP1617844A4 (en) | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
EP1651169A4 (en) | 2003-08-01 | 2008-02-27 | Medarex Inc | POLYTHERAPIES FOR MULTIPLE SCLEROSIS |
US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
US20060276537A1 (en) | 2005-06-01 | 2006-12-07 | Tamar Goren | Use of ladostigil for the treatment of multiple sclerosis |
CA2623955C (en) | 2005-09-23 | 2019-12-17 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
TWM331106U (en) * | 2007-11-12 | 2008-04-21 | Syspotek Corp | Solution counter with temperature sensor |
UY32109A (es) | 2008-09-10 | 2010-04-30 | Acorda Therapeutics Inc | Métodos para utilizar composiciones de liberación sostenida de aminopiridina |
WO2010090730A1 (en) | 2009-02-03 | 2010-08-12 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
KR20170034452A (ko) | 2009-02-11 | 2017-03-28 | 아코르다 쎄라퓨틱스 인코포레이티드 | 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법 |
JO3348B1 (ar) | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
AR078323A1 (es) | 2009-09-04 | 2011-11-02 | Acorda Therapeutics Inc | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple |
US10255905B2 (en) | 2016-06-10 | 2019-04-09 | Google Llc | Predicting pronunciations with word stress |
-
2005
- 2005-04-08 US US11/102,559 patent/US8354437B2/en active Active
- 2005-04-11 DK DK05732613.4T patent/DK1732548T4/da active
- 2005-04-11 WO PCT/US2005/012427 patent/WO2005099701A2/en active Application Filing
- 2005-04-11 PT PT111602470T patent/PT2377536E/pt unknown
- 2005-04-11 HR HRP20110497TT patent/HRP20110497T4/hr unknown
- 2005-04-11 ME MEP-2011-321A patent/ME01721B/me unknown
- 2005-04-11 CA CA2562277A patent/CA2562277C/en active Active
- 2005-04-11 JP JP2007507570A patent/JP5736100B2/ja active Active
- 2005-04-11 PT PT05732613T patent/PT1732548E/pt unknown
- 2005-04-11 EP EP20110168901 patent/EP2422782A1/en not_active Withdrawn
- 2005-04-11 EP EP11160247.0A patent/EP2377536B2/en active Active
- 2005-04-11 CA CA2870734A patent/CA2870734C/en active Active
- 2005-04-11 AT AT05732613T patent/ATE511841T1/de active
- 2005-04-11 PL PL11160247.0T patent/PL2377536T5/pl unknown
- 2005-04-11 DK DK11160247.0T patent/DK2377536T4/da active
- 2005-04-11 ES ES05732613T patent/ES2367707T5/es active Active
- 2005-04-11 EP EP11179067.1A patent/EP2460521B1/en not_active Revoked
- 2005-04-11 SI SI200531728T patent/SI2377536T2/sl unknown
- 2005-04-11 ME MEP-2013-48A patent/ME01836B/me unknown
- 2005-04-11 SI SI200531307T patent/SI1732548T2/sl unknown
- 2005-04-11 RS RS20110321A patent/RS51808B2/sr unknown
- 2005-04-11 MX MXPA06011648A patent/MXPA06011648A/es active IP Right Grant
- 2005-04-11 RS RS20130183A patent/RS53371B2/sr unknown
- 2005-04-11 AU AU2005232732A patent/AU2005232732B2/en active Active
- 2005-04-11 EP EP21170762.5A patent/EP3922248A1/en active Pending
- 2005-04-11 EP EP05732613.4A patent/EP1732548B2/en active Active
- 2005-04-11 MX MX2015004339A patent/MX370434B/es unknown
- 2005-04-11 PL PL05732613T patent/PL1732548T4/pl unknown
- 2005-04-11 ES ES11179067T patent/ES2746354T3/es active Active
- 2005-04-11 HU HUE11179067A patent/HUE046320T2/hu unknown
-
2006
- 2006-10-09 MX MX2019015036A patent/MX2019015036A/es unknown
-
2010
- 2010-06-25 US US12/824,136 patent/US20110166189A1/en not_active Abandoned
- 2010-06-25 US US12/824,135 patent/US20110166188A1/en not_active Abandoned
- 2010-06-25 US US12/824,133 patent/US20110166187A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100757T patent/CY1111754T1/el unknown
- 2011-11-18 US US13/299,969 patent/US8440703B2/en active Active
-
2012
- 2012-01-18 LU LU91933C patent/LU91933I2/fr unknown
- 2012-01-19 FI FIEP05732613.4T patent/FI1732548T4/fi active
- 2012-01-19 CY CY2012004C patent/CY2012004I1/el unknown
- 2012-03-02 US US13/410,388 patent/US20120164078A1/en active Pending
- 2012-04-18 HK HK12103854.5A patent/HK1162971A1/xx active IP Right Maintenance
- 2012-04-25 JP JP2012100498A patent/JP2012188427A/ja active Pending
-
2013
- 2013-03-14 US US13/829,221 patent/US20140039015A1/en not_active Abandoned
- 2013-04-29 CY CY20131100351T patent/CY1114073T1/el unknown
- 2013-05-14 HR HRP20130424TT patent/HRP20130424T4/hr unknown
- 2013-08-13 FI FIC20130042C patent/FIC20130042I1/fi unknown
- 2013-09-03 LU LU92275C patent/LU92275I2/xx unknown
- 2013-09-05 CY CY2013035C patent/CY2013035I1/el unknown
-
2014
- 2014-11-03 US US14/531,191 patent/US20150080436A1/en not_active Abandoned
- 2014-12-24 JP JP2014259950A patent/JP5914626B2/ja active Active
-
2015
- 2015-06-05 JP JP2015114746A patent/JP2015157861A/ja not_active Withdrawn
-
2016
- 2016-03-23 US US15/079,010 patent/US20160199358A1/en not_active Abandoned
- 2016-11-04 US US15/344,096 patent/US20170071924A1/en not_active Abandoned
-
2017
- 2017-04-07 US US15/482,432 patent/US20170273960A1/en not_active Abandoned
- 2017-04-07 US US15/482,426 patent/US9925173B2/en active Active
-
2018
- 2018-03-12 US US15/918,931 patent/US20180200241A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
JPN6011055474; SCHWID, S. R. et al: 'Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple s' NEUROLOGY vol.48, no.4, 1997, p.817-821 * |
JPN6011055478; BEVER, C. T. Jr. et al: 'The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-cont' NEUROLOGY vol.44, no.6, 1994, p.1054-1059 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5914626B2 (ja) | 徐放性アミノピリジン組成物の使用方法 | |
US20240041850A1 (en) | Methods of Using Sustained Release Aminopyridine Compositions | |
AU2018202552B2 (en) | Methods of using sustained release aminopyridine compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121001 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121001 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140415 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140418 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140507 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140512 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141028 |